Epidermolysis Bullosa Simplex, Epidermolysis Bullosa Simplex Kobner, Weber-Cockayne Syndrome
Conditions
Keywords
Epidermolysis bullosa simplex
Brief summary
: Epidermolysis bullosa (EB) simplex is a rare orphan disease caused by a mutation in DNA leading to abnormal dominant keratins in the skin. Patients with EB simplex develop lifelong painful thick soles on their feet, and current standard of care is supportive. This pilot study will target the dominant mutant keratin proteins in the skin to ameliorate the severity of EB simplex. The purpose is to improve the function of EB simplex feet with an application of topical sirolimus, 2%. The investigators plan on inhibiting the mTOR pathway to down regulate the translation of defective keratin proteins and work through anti proliferative pathways.
Detailed description
The proposed 40 week pilot study being conducted is a prospective, double-blind, randomized, placebo-controlled crossover study. Participants will be assigned to treat both feet with either topical sirolimus, 2% cream daily or placebo (vehicle-control) for 12 weeks, followed by a 4 week washout period, then re-treatment to both feet will occur by the cross-over intervention. These studies will exploit the naturally occurring transcriptional regulation of keratin sequences, the known gene aberration causing EB simplex, and assess the potential for mTOR pathway inhibition in treatment of the patient's plantar lesions. The objective of this study is to assess (1) the safety of topical rapamycin for plantar lesions for the treatment of EB simplex, and 2) test if topical rapamycin to improves the clinical severity of lesional skin, including pain and itch, in subjects with EB simplex at the end of treatment versus baseline and compared to an intrasubject placebo treated control. Wound size measurement, quality of life evaluation will be assessed using epidermolysis bullosa (QOLEB), and EB disease activity and Scarring Index (EBDASI). With the results of this pilot study, physicians would be able to transition from supportive care (the current state of the art for EB simplex) to targeted molecular therapeutics, leading to improved mobility and quality of life for patients with EB simplex.
Interventions
DRUGSirolimus 2%
DRUGVehicle
Sponsors
Premier Specialists, Australia
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
5 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Subjects must: * Be capable of understanding the purpose and risks of the study and sign a written Informed Consent Form (ICF); Legally authorized representative of subjects willing and able to give consent for children 5-18 yo * Be male or female with a diagnosis of EBS * Minimum EBDASI feet activity score of 2/10 * Age - 5 years or older * Ability to complete 12 study visits within a 40-week period, each for approximately 30-60 minutes. Anticipated life expectancy ≥52 weeks * Males and females of childbearing potential should be using an effective means of contraception. * Laboratory values within the range of normal for the participating institution unless the PI feels they are not clinically relevant * Be able to comply with all study requirements
Exclusion criteria
* Allergy to sirolimus or components of the vehicle ointment * Pregnancy, breast feeding * Prior history of liver disease * Serious known concurrent medical illness or infection, which could potentially present a safety risk and/or prevent compliance with the requirements of the treatment program. * Known immunodeficiency virus or syndrome including those with: * Acquired Immunodeficiency Syndrome (AIDS) * Human Immunodeficiency Virus (HIV) * Hepatitis B * Prior history of grafting surgeries or other surgeries in the dermatologic treatment area * History of significant condition in the dermatologic treatment area such as trauma, which could impair evaluation for the treatment of EBS or non-healing chronic wound. * Use of other investigational drugs within 30 days of the screening visit and/or has not recovered from any side effects of prior investigational drugs or procedure in the affected area (e.g., a biopsy). * Use of acitretin within the last 1 month * Use of Roaccutane within last 3 months * Botox injections to the feet within the last 6 months. * Participant is planning extra physical activities within the next 3 months. * Amputated foot
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Foot Health Status Questionnaire | Change from Baseline to End of Treatment completion at 32 Week | Foot function utilizing the validated Foot Health Status Questionnaire (FHSQ) as a change from baseline to the end of each treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| FitBit® / pedometer | Baseline and through study treatment completion at 32-weeks] | — |
| Plantar defect size using 3D Photography | Change in total defect area from Baseline, clinical visits at Week 4, Week 12, Week 16, Week 28, through study treatment completion at 32-weeks | Plantar defect size measurements using 3D photography (% change in total defect area) from baseline to the end of each treatment. |
| Child Dermatological Quality of Life Questionnaire | Baseline through study treatment completion at 32 weeks | — |
| The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) Disease Severity Scale | Baseline and through study treatment completion at 32-weeks | — |
Countries
Australia
Contacts
Primary ContactDedee F Murrell, MD
Backup ContactCharmaine Peras
Outcome results
None listed